CMN-001 for Carcinoma

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Carcinoma+2 More
CMN-001 - Biological
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new immunotherapy treatment for renal cell carcinoma. The treatment involves taking dendritic cells from the patient, loading them with RNA from the patient's tumor, and then injecting them back into the patient. The treatment is given in combination with other drugs.

Eligible Conditions
  • Carcinoma
  • Advanced Renal Cell Carcinoma (aRCC)

Treatment Effectiveness

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: Through study completion, an average of 2 years

Year 2
Monitor treatment emergent adverse events between both arms
Overall Survival
Progression free survival
Tumor Response

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

2 Treatment Groups

Standard Treatment
1 of 2
Combination Arm
1 of 2

Active Control

Experimental Treatment

120 Total Participants · 2 Treatment Groups

Primary Treatment: CMN-001 · No Placebo Group · Phase 2

Combination ArmExperimental Group · 3 Interventions: Nivolumab+Ipilimumab, Lenvatinib+Everolimus, CMN-001 · Intervention Types: Biological, Drug, Biological
Standard TreatmentActiveComparator Group · 2 Interventions: Nivolumab+Ipilimumab, Lenvatinib+Everolimus · Intervention Types: Biological, Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, an average of 2 years

Who is running the clinical trial?

CoImmuneLead Sponsor

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have histologically confirmed advanced renal cell carcinoma.
Subjects who are candidates for standard first-line therapy.
Resolution of all acute toxic effects of prior radiotherapy or surgical procedures to Grade ≤ 1 according to NCI CTCAE.
Platelets 75,000/mm3 or 75.0 x 109/L or greater.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 31st, 2021

Last Reviewed: November 17th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.